Pick Biotech Winners Like A Pro: John McCamant Seeking Alpha That would be a huge leg up for the stock, at another 100 points. TLSR: And the B-cell lymphomas are a great trail to follow. JM: Exactly. When Rituxin [rituximab] was in development, it was a niche product that cost Genentech [a Roche Holding AG (RHHBY. |
